QR Kod

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research

Abstract Background Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC, many patients will relapse and the PARPi-resistant setting is an area of unmet m...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Aurélie Moniot, Christophe Schneider, Laure Chardin, Elisa Yaniz-Galende, Catherine Genestie, Marion Etiennot, Aubéri Henry, Coralie Drelon, Audrey Le Formal, Benoit Langlois, Laurence Venat, Christophe Louvet, Laure Favier, Alain Lortholary, Dominique Berton-Rigaud, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Coraline Dubot, Jean Emmanuel Kurtz, Nathalie Bonichon Lamichhane, Éric Pujade-Lauraine, Albin Jeanne, Alexandra Leary, Stéphane Dedieu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMC 2024-08-01
Seri Bilgileri:Molecular Cancer
Konular:
Ovarian cancer
TSP-1
CD47
PARP
Neoadjuvant chemotherapy
Online Erişim:https://doi.org/10.1186/s12943-024-02073-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller